** Shares of drug developer Marker Therapeutics MRKR.O fall 25.5% to $3 premarket
** MRKR announces $16.1 mln private placement
** Proceeds from this financing will support the clinical development of MT-601, a next-generation T cell-based therapy for relapsed lymphoma patients - MRKR
** Investors to pay a purchase price of $3.20/shr and warrants are exercisable for $4.03/shr
** As of last close, stock has fallen 26.7% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。